Clinical Trial Update: Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 [Phase 1]

View source ↗

Summary

This withdrawal notice reports that a Phase 1 trial evaluating fenofibrate's effects on biomarkers related to CP-742,033 in obesity has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CP-742,033
• FENOFIBRATE (Fenofibrate)

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 1 | Status: WITHDRAWN